Ardea Biosciences fourth one fourth net reduction decreases to $0.6 million Ardea Biosciences, Inc androgen-alopecia.html . , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported recent accomplishments and announced 4th quarter and full-year 2010 financial results. ‘With around $160 million in cash as of the finish of February, we are in an excellent financial position,’ commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.’ Latest Accomplishments and Important Upcoming Events In December 2010, the United States Adopted Titles Counsel followed lesinurad, pronounced ‘le sin' ure ad’, as the USAN name for RDEA594.
Placebo-corrected reductions from baseline of around 40 percent were observed after 28 days in the twice-daily dosing group, which was consistent with reductions seen in previous studies of RDEA806 in normal, healthful volunteers. RDEA806 was well-tolerated also. There were no serious adverse events or discontinuations due to adverse events, and there was no factor in the rates of adverse events across medication – and placebo-treated groups. Third , successful demonstration of proof-of-idea in gout patients, all further studies in gout pain will be carried out with RDEA594 directly. Quart, PharmD, Ardea's president and chief executive officer. Mark C. Genovese, professor of medicine, co-chief of the division of immunology and rheumatology at Stanford University Medical Center and a participant in today's professional panel conversation.